Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain
| dc.contributor.author | Cantarero, David | |
| dc.contributor.author | Ocaña, Daniel | |
| dc.contributor.author | Onieva-García, María Ángeles | |
| dc.contributor.author | Rodríguez-García, Juan | |
| dc.contributor.author | Gálvez, Paulina | |
| dc.contributor.author | Méndez, Cristina | |
| dc.contributor.author | Crespo Palomo, Carlos | |
| dc.contributor.author | López-Ibáñez de Aldecoa, Alejandra | |
| dc.date.accessioned | 2025-02-19T12:34:37Z | |
| dc.date.available | 2025-02-19T12:34:37Z | |
| dc.date.issued | 2023-08-14 | |
| dc.date.updated | 2025-02-19T12:34:37Z | |
| dc.description.abstract | A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcal pneumonia (NBP) and invasive pneumococcal disease (IPD). | |
| dc.format.extent | 8 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 738565 | |
| dc.identifier.issn | 0264-410X | |
| dc.identifier.uri | https://hdl.handle.net/2445/218975 | |
| dc.language.iso | eng | |
| dc.publisher | Elsevier B.V. | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.vaccine.2023.07.016 | |
| dc.relation.ispartof | Vaccine, 2023, vol. 41, num.36, p. 5342-5349 | |
| dc.relation.uri | https://doi.org/10.1016/j.vaccine.2023.07.016 | |
| dc.rights | cc-by-nc-nd (c) Elsevier B.V., 2023 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
| dc.source | Articles publicats en revistes (Genètica, Microbiologia i Estadística) | |
| dc.subject.classification | Vacuna antipneumocòccica | |
| dc.subject.classification | Anàlisi cost-benefici | |
| dc.subject.other | Pneumococcal vaccine | |
| dc.subject.other | Cost effectiveness | |
| dc.title | Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/acceptedVersion |
Fitxers
Paquet original
1 - 1 de 1